Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue remains negative
Q1 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $0.
Context
- Cost of revenue increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's LTM Mar 2026 cost of revenue of $0 is the lowest of the 6 companies compared; the peer median is $180.63K.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.86M | — | — | — | |
| LTM Mar 2026 | $6.01M | +9.4% | +4.5% | 4.0% | |
| LTM Mar 2026 | $180.63K | +300.0% | — | 12.8% | |
| LTM Mar 2026 | $108K | — | — | — | |
| LTM Mar 2026 | $79K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding TELO) | $180.63K | +154.7% | +4.5% | 8.4% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.49K | 833.21K | 1.57M | 2.24M | 2.44M |
| Selling, General & Admin | 11.64K | 20.94K | 600.19K | 9.64M | 8.1M |
| Operating Expenses | 138.13K | 854.15K | 3.94M | 12.24M | 10.54M |
| Depreciation & Amortization | 138.13K | 854.15K | 0 | 12.24M | 0 |
| EBITDA | 0 | 0 | (11.43M) | 48K | (10.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (138.13K) | (854.15K) | (3.94M) | (12.24M) | (10.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 48K | 125.64K |
| Interest Expense | 0 | 0 | 1.64M | (4.34M) | 0 |
| Other Income / Expenses | 0 | 0 | (9.13M) | (4.29M) | 125.64K |
| Income Before Tax | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| EPS (Diluted) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| Weighted Avg Shares | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
| Weighted Avg Shares (Diluted) | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.